Tin tức & Cập nhật
Lọc theo Chuyên ngành:

AFP-L3, DCP predict HCC recurrence after liver transplant
Dual positivity for alpha-fetoprotein (AFP) bound to Lens culinaris agglutinin (AFP-L3) ≥15 percent and des-gamma-carboxyprothrombin (DCP) ≥7.5 can strongly predict majority of early hepatocellular carcinoma (HCC) recurrences following liver transplantation (LT), suggests a study.
AFP-L3, DCP predict HCC recurrence after liver transplant
13 Dec 2023
Molecular-based guided therapy shows promise in treatment-resistant HCC/H-CCK
A recent study has demonstrated the feasibility of molecular-based targeted therapy in patients with hepatocellular carcinoma (HCC)/hepato-cholangiocarcinoma (H-CCK) that progressed while under treatment with atezolizumab/bevacizumab.
Molecular-based guided therapy shows promise in treatment-resistant HCC/H-CCK
12 Dec 2023
Hepatocellular carcinoma risk diminishes with time following HCV eradication
Among individuals with cirrhosis and cured hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma tapers off progressively through 6 years after HCV eradication, as shown in a study. However, the risk remains above thresholds that require screening.
Hepatocellular carcinoma risk diminishes with time following HCV eradication
30 Nov 2023
Novel tri-agonist confers significant gains for MASLD patients
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.